Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,035 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,952 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01965353 | A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma(PanRVD) | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01723020 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 107 | Kartos Therapeutics, Inc.INDUSTRY | 3 | Sep 2, 2021 |
| NCT00052442 | 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 72 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT01767766 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 90 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 23, 2021 | clinicaltrials |
| NCT02481934 | Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma(NK-VS-MM) | completed | Phase 1 | 5 | Joaquín Martínez López, MD, PhDOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT00061425 | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG | completed | Phase 1 / Phase 2 | — | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT00596804 | Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 39 | Gilead SciencesINDUSTRY | 2 | Aug 18, 2021 | clinicaltrials |
| NCT00285428 | Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 82 | Gilead SciencesINDUSTRY | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01449461 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) | completed | Phase 1 / Phase 2 | 137 | Ariad PharmaceuticalsINDUSTRY | 0 | Aug 17, 2021 | clinicaltrials |
| NCT03383055 | CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig | completed | Phase 1 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT00421395 | Safety Study of NHL With 90Y-hLL2 IgG | completed | Phase 1 / Phase 2 | 59 | Gilead SciencesINDUSTRY | 2 | Aug 16, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT00546793 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | completed | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | completed | Phase 1 | 197 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 4, 2021 | clinicaltrials |
| NCT01221857 | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 12 | Gamida Cell ltdINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT00406809 | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 81 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Aug 2, 2021 | clinicaltrials |
| NCT01794507 | A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy | completed | Phase 1 | 66 | AbbVieINDUSTRY | 3 | Aug 2, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03665155 | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT02594267 | A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | completed | Phase 1 | 48 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jul 27, 2021 | clinicaltrials |
| NCT02650999 | Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas | completed | Phase 1 / Phase 2 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT03555955 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | completed | Phase 1 | 21 | Jazz PharmaceuticalsINDUSTRY | 2 | Jul 22, 2021 | clinicaltrials |
| NCT02973113 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)(PREVALE) | completed | Phase 1 | 8 | Baylor College of MedicineOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT02432235 | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | completed | Phase 1 | 133 | ADC Therapeutics S.A.INDUSTRY | 2 | Jul 13, 2021 | clinicaltrials |
| NCT02283775 | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients(PomdeSAR) | completed | Phase 1 | 54 | SanofiINDUSTRY | 1 | Jul 9, 2021 | clinicaltrials |
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | completed | Phase 1 / Phase 2 | 14 | Cancer Research UKOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03730363 | Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma | completed | Phase 1 | 1 | Reinhold MunkerOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT00794638 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 9 | SymBio PharmaceuticalsINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT02906371 | Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | completed | Phase 1 | 80 | University of PennsylvaniaOTHER | 1 | Jul 2, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT04082286 | Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia | completed | Phase 1 | 9 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT04171791 | A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) | completed | Phase 1 | 4 | Yale UniversityOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | completed | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2021 | clinicaltrials |
| NCT00562978 | Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 0 | Jun 18, 2021 | clinicaltrials |
| NCT02569320 | HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 9 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT01188681 | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 79 | Aptevo TherapeuticsINDUSTRY | 5 | Jun 10, 2021 | clinicaltrials |
| NCT01861002 | A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | completed | Phase 1 | 15 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Jun 9, 2021 | clinicaltrials |
| NCT03259529 | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL(BeGeRN) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT02609230 | A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | completed | Phase 1 | 33 | Fox Chase Cancer CenterOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT03239392 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | completed | Phase 1 / Phase 2 | 50 | Bioniz TherapeuticsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT03885947 | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | completed | Phase 1 | 7 | Alla KeyznerOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT03498430 | Copanlisib Chinese PK Study | completed | Phase 1 | 13 | BayerINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT03892421 | Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 22 | La Raza Medical CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT00792467 | Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 24 | ItalfarmacoINDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT02129582 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | completed | Phase 1 / Phase 2 | 22 | Boston Medical CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Sep 5, 2021source: clinicaltrials